About this trial
Sodium (Na+) hemostasis is abnormal in CKD patients, and this element can be deposited in the skin, muscle, and skeleton - to cope with long term sodium loading. It is known that sodium stored in this non-osmotically active way, is profoundly inflammatory. Furthermore, inflammation has been associated with several uremic symptoms. The investigators will use novel Na+ MRI imaging to examine the Na+ deposition in the skin, muscle, and skeleton of five groups:1) chronic in-center hemodialysis patients, 2) chronic peritoneal dialysis patients, 3) adult and paediatric patients with CKD stage 1-5 and 4) heart failure patients with and without renal dysfunction 5) sex and age-matched healthy adult and paediatric controls. Additionally, they will investigate the association between sodium deposition in these tissues with uremic symptomatology and biochemical markers of metabolism.
Eligibility criteria
Qualifiers
Age greater than or equal to 6 years
For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy
For patients with CKD stage 1-5: CKD stage 1-5 and no indications to start dialysis
For heart failure patients: with or without renal dysfunction
Disqualifiers
Pregnant, breastfeeding or intending pregnancy
Unable to give consent or understand written information
Contraindication to MRI study
Trial design
Treatments tested in this trial
- Measuring sodium content
Treatment groups
Sponsors and collaborators
Chris McIntyre
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor institution